Adenovirus-based Gene Therapy: Therapeutic Angiogenesis with Adenovirus 5 Fibroblast Growth Factor-4 (Ad5FGF-4) in Patients with Chronic Myocardial Ischemia

Modern Biopharmaceuticals: Design, Development and Optimization

Volumn 1, Issue , 2008, Pages 151-181

  Mccaman, Michael ^a   Castillo, Francisco J ^a   Fawaz, Farah ^a   Ogawa, Yasushi ^a   Whiteley, Erik ^a   Lehmberg, Elisabeth ^a   Tan, Mei ^a   Kung, Jacob ^a   Mann, Bruce ^a   Pungor Jr , Erno ^a   Rubanyi, Gabor M ^a  

^a BAYER AG   (Germany)

Author keywords

Adenovirus 5; Fractogel; Ischemia; Shuttle vector; Ultra filtration

Indexed keywords

EID: 34547806456     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527620982.ch6     Document Type: Chapter

References (54)

1. European Society of Cardiology. Management of stable angina pectoris: recommendation of the Task Force of the European Society of Cardiology. Eur Heart J 1997; 18:394-413.
2. Isner JM. Angiogenesis and collateral formation. In: March KL, Ed. Gene Transfer in the Cardiovascular System: Experimental Approaches and Therapeutic Implications. Boston: Kluwer Academic Publishers, 1997; pp. 307-330.
3. Rubanyi GM. The future of human gene therapy. Mol Aspects Med 2001; 22:113-142.
4. Wustman K, Zbinden S, Windecker S, Meier B, Seiler C. Is there functional collateral flow during vascular occlusion in angiographically normal coronary arteries? Circulation 2003; 107:2213-2220.
5. Hansen JF. Coronary collateral circulation: clinical significance and influence on survival in patients with coronary artery occlusion. Am Heart J 1989; 117:290-295.
6. Unger EF, Banai S, Shou M, Jaklitsch M, Hodge E, Correa R, Jaye M, Epstein SE. A model to assess interventions to improve collateral blood flow: continuous administration of agents into the left coronary artery in dogs. Cardiovasc Res 1993; 27:785-791.
7. Harada K, Grossman W, Friedman M, et al. Basic fibroblast growth factor improves myocardial function in chronically ischemic porcine hearts. J Clin Invest 1994; 94:623-630.
8. Giordano FJ, Ping P, McKirnan MD, et al. Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nature Med 1996; 2:534-539.
9. Losordo DW, Vale PR, Symes JF, et al. Gene therapy for myocardial angio-genesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 1998; 98:2800-2804.
10. Rosengart TK, Lee LY, Patel SR, et al. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 1999; 100:468-474.
11. Rosengart TK, Lee LY, Patel SR, et al. Sixmonth assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA. Ann Surg 1999; 230:466-470.
12. Vale PR, Losordo DW, Milliken CE, et al. Randomized, single-blind, placebo-controlled pilot study of catheter-based myocardial gene transfer for therapeutic angiogenesis using left ven- tricular electromechanical mapping in patients with chronic myocardial ischemia. Circulation 2001; 103:2138-2143.
13. Grines CL, Watkins MW, Helmer G, et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 2002; 105(11):1291-1297.
14. Grines CL, Watkins M, Mahmarian J, et al. A randomized double blind placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J Am Coll Cardiol 2003; 42:1339-1347.
15. Ylä-Herttuala S, Martin JF. Cardiovascular gene therapy. Lancet 2000; 355:213-222.
16. Schumacher B, Pecher P, von Specht BU, et al. Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. Circulation 1998; 97:645-650.
17. Laitinen M, Hartikainen J, Hiltunen MO, et al. Catheter-mediated vascular endothelial growth factor gene transfer to human coronary arteries after angioplasty. Hum Gene Ther 2000; 11:263-270.
18. Khurana R, Simons M. Insights from angiogenesis trials using fibroblast growth factor for advanced arteriosclerotic disease. Trends Cardiovasc Med 2003; 13:116-122.
19. Bush MA, Samara E, Whitehouse MJ, et al. Pharmacokinetics and pharmacodynamics of recombinant FGF-2 in a phase I trial in coronary artery disease. J Clin Pharmacol 2001; 41:378-385.
20. Simons M, Annex BH, Laham RJ, et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation 2002; 105:788-793.
21. Ruel M, Laham RJ, Parker JA, et al. Longterm effects of surgical angiogenic therapy with fibroblast growth factor 2 protein. J Thorac Cardiovasc Surg 2002; 124:28-34.
22. Isner JM, Vale PR, Symes JF, et al. Assessment of risks associated with cardiovascular gene therapy in human subjects. Circ Res 2001; 89:389-400.
23. Carmeliet P. Angiogenesis in health and disease. Nature Med 2003; 9:653-660.
24. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nature Med 2003; 9:677-684.
25. Ylä-Herttuala S, Alitalo K. Gene transfer as a tool to induce therapeutic vascular growth. Nature Med 2003; 9:694-701.
26. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nature Med 2003; 9:669-676.
27. Rissanen TT, Markkanen JE, Arve K, et al. Fibroblast growth factor-4 induces vascular permeability, angiogenesis and arteriogenesis in a rabbit hindlimb ischemia model. FASEB J 2003; 17:100-102.
28. Barbato JG, Tzeng E. Nitric oxide and arterial disease. J Vasc Surg 2004; 40:187-193.
29. Onimaru M, Yonemitsu Y, Tanii M, et al. Fibroblast growth factor-2 gene transfer can stimulate hepatocyte growth factor expression irrespective of hypoxia-mediated downregulation in ischemic limbs. Circ Res 2002; 91:923-930.
30. Deindl E, Fernández B, Höfer IE, et al. Arteriogenesis, collateral blood vessels, and their development. In: Rubanyi GM, Ed. Angiogenesis in Health and Disease. New York: Marcel Dekker; 2000; pp. 31-45.
31. House SL, Bolte C, Zhou M, et al. Cardiacspecific overexpression of fibroblast growth factor-2 protects against myocardial dysfunction and infarction in a murine model of lowflow ischemia. Circulation 2003; 108:3140-3148.
32. Losordo DW, Vale PR, Hendel RC, et al. Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation 2002; 105:2012-2018.
33. Hedman M, Hartikainen J, Syvanne M, et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 2003; 107:2677-2683.
34. Boekstegers P. Perspectives on selective retroinfusion of coronary veins as an alternative approach for myocardial gene transfer and angiogenesis. J Invasive Cardiol 2001; 13:339-342.
35. Delli Bovi P, Curatola AM, Kern FG, et al. An oncogene isolated by transfection of Kaposi's sarcoma DNA encodes a growth factor that is a member of the FGF family. Cell 1987; 50:729-737.
36. Gomez-Foix AM, Coats WS, Baque S, et al. Adenovirus-mediated transfer of the muscle glycogen phosphorylase gene into hepatocytes confers altered regulation of glycogen metabolism. J Biol Chem 1992; 267:25129-25134.
37. McGrory WJ, Bautista DS, Graham FL. A simple technique for the rescue of early region 1 mutations into infectious human Adenovirus Type 5. Virology 1988; 163:614-617.
38. Bett AJ, Krougliak V, Graham FL. DNA sequence of the deletion/insertion in early region 3 of Ad5 dl309. Virus Res 1995; 39:75-82.
39. Schoofs G, Monica T, Ayala J, et al. A high yielding serum-free cell culture process to manufacture recombinant adenoviral vectors for gene therapy. Cytotechnology 1998; 28:81-89.
40. Huyghe BG, Liu X, Sutjipto S., et al. Purification of a type 5 adenovirus encoding human p53 by column chromatography. Human Gene Ther 1995; 6:1403-1416.
41. Mann B, Traina J, Soderbloom C, et al. Capillary zone electrophoresis of a recombinant adenovirus. J Chromatogr A 2000; 895:329-337.
42. Lehmberg E, Traina JA, Chakel JA, et al. Reversed- phase high performance liquid chromatographic assay for the adenovirus type 5 proteome. J Chromatogr B 1999; 732:411-423.
43. Lehmberg E, McCaman M, Traina J, et al. Analytical assays to characterize adenoviral vectors and theoretic applications. In: Subramanian G, Ed. Manufacturing of Gene Therapeutics. Kluwer Academic/Plenum Press, 2004; pp. 210-225.
44. Murakami P, Pungor E, Files J, et al. A single short stretch of homology between adenoviral vector and packaging cell line can give rise to cytopathic effect-inducing, helper-dependent E1-positive particles. Human Gene Ther 2002; 13:909-920.
45. Murakami P, Havenga M, Fawaz F, et al. Common structure of rare replication-deficient E1-positive particles in adenoviral vector batches. J Virol 2004; 78:6200-6208.
46. Walsh PS, Varlaro J, Reynolds R. A rapid chemiluminescent method for quantitation of human DNA. Nucleic Acids Res 1992; 20:5061-5065.
47. Chroboczek J, Bieber F, Jacrot B. The sequence of the genome of adenovirus type 5 and its comparison with the genome of adenovirus type 2. Virology 1992; 186(1):280-285.
48. Thimmappaya B, Jones N, Shenk T. A mutation which alters initiation of transcription by RNA Polymerase III on the Ad5 chromosome. Cell 1979; 18:947-954.
49. Sugarman BJ, Hutchins BM, McAllister DL, et al. The complete nucleic acid sequence of the Adenovirus Type 5 Reference Material (ARM) genome. Bioprocess J 2003; 2(5):27-33.
50. Chirmule N, Propert K, Magosin S, et al. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther 1999; 6:1574-1583.
51. Molinier-Frenkel V, Gahery-Segard H, Mehtali M, et al. Immune response to recombinant adenovirus in humans: capsid components from the viral input are targets for vector-specific cytotoxic T lymphocytes. J Virol 2000; 74(16):7678-7682.
52. Watkins MW, Rubanyi GM. Gene therapy for coronary artery disease: Preclinical and initial clinical results with intracoronary administration of Ad5FGF-4. In: Rubanyi GM & Ylä-Herttuala S, Eds. Human Gene Therapy: Current Opportunities and Future Trends. Berlin: Springer, 2003; pp. 61-80.
53. Gao MH, Lai NC, McKirnan MD, et al. Increased regional function and perfusion after intracoronary delivery of adenovirus encoding fibroblast growth factor-4: Report of preclinical data. Human Gene Ther 2004; 15:574-587.
54. Rubanyi GM. The design and preclinical testing of Ad5FGF-4 to treat chronic myocardial ischemia. Eur Heart J (Suppl. E) 2004; 6:E12-E17.